We connect people with life-changing medicine across Europe, the UK and beyond.
Our insights help each and every patient make the most of their medicine to keep their lives on track.
Our key markets
We provide bespoke end-to-end services across Europe, the UK and beyond in our key markets to connect pharmaceutical companies, insurers and healthcare professionals to patients.
Rare diseases
We’re a global network dedicated to getting rare and orphan medicines to hard-to-reach patients worldwide.
Sciensus Digital+
We elevate patient care by combining advanced digital platforms with a personalised “human touch”.
Long-term conditions
As a leading life science business, we help those with long-term conditions get the best from their medicines.
Cancer treatments
Delivering a range of treatments, we are the UK’s leading provider of cancer in-home care.
Services built on exceptional insight and experience
Connecting pharmaceutical companies, insurers and healthcare professionals to patients. With global headquarters in Switzerland and London, localised distribution networks in the Netherlands serving Europe and a multi-lingual customer services team based in Germany, Sciensus is improving health outcomes for patients around the world.
Leading the way for 30 years
Safe, reliable medicines dispensing
Unparalleled clinical expertise
As a strategic partner, they have exceeded our expectations by finding global patients, who need our drugs, and enabling them to receive their life-extending medications.
Chief Commercial Officer at Eiger BioPharmaceuticals, Inc.
News and Insights
Stay up to date with the news and learn from our experts across Sciensus.
Blogs/Articles
Four considerations before collecting real-world data in your EAP
Expanded access programs (EAPs) for rare disease medications present a valuable opportunity for biotechs to collect real-world data (RWD). In…
Blogs/Articles
The increasing importance of real-world data for the EMA
Over recent years, real-world data (RWD) has become a critical element of the development and commercialization of medications. RWD includes…
Blogs/Articles
Six steps for a successful Expanded Access Program in Europe
For biotech companies seeking to bring a new rare disease treatment to market in Europe, there can be many obstacles…
